Condition
Primary Mediastinal B Cell Lymphoma clinical trials and research
As of November 12, 2026, Find a Trial lists 4 Primary Mediastinal B Cell Lymphoma clinical trials that are recruiting, in United States. By phase: Phase 2 (2), Phase 1/2 (1). Every study is explained in plain English. Data from ClinicalTrials.gov and NIH RePORTER, updated November 12, 2026.
- 4Clinical trials
- 1Country
Newest Primary Mediastinal B Cell Lymphoma clinical trials
| Study | Phase | Where | Status | Registered |
|---|---|---|---|---|
| Non-Hodgkin Lymphoma Sample Collection for MRD Testing | — | Austin, Texas | Recruiting | Aug 6, 2026 |
| UB-VV400 with rapamycin in relapsed/refractory B-cell lymphomas | Phase 1/2 | Irvine, California and 1 other locations | Recruiting | Jul 30, 2026 |
| Ruxolitinib plus pembrolizumab for relapsed or refractory Hodgkin and non-Hodgkin lymphomas | Phase 2 | New York, New York | Recruiting | Dec 16, 2025 |
| Using obinutuzumab with chemotherapy for relapsed CD20+ Non-Hodgkin Lymphoma in young patients | Phase 2 | Valhalla, New York | Recruiting | Mar 19, 2015 |
All recruiting trials (4)
-
Non-Hodgkin Lymphoma Sample Collection for MRD Testing
This study tests a blood-based and tissue-based approach to see if a molecular residual disease test can detect lingering cancer in adults with aggressive NHL who are starting standard therapy.
-
UB-VV400 with rapamycin in relapsed/refractory B-cell lymphomas
A phase 1/2 trial tests UB-VV400 plus rapamycin in adults with relapsed or refractory B-cell lymphomas to see if it is safe and shows anti-tumor activity.
-
Ruxolitinib plus pembrolizumab for relapsed or refractory Hodgkin and non-Hodgkin lymphomas
This trial will try adding ruxolitinib to pembrolizumab to see if it is safe and helps people whose Hodgkin or non-Hodgkin lymphomas have come back or did not respond to prior treatment.
-
Using obinutuzumab with chemotherapy for relapsed CD20+ Non-Hodgkin Lymphoma in young patients
This study is testing if a new drug called obinutuzumab, alone or with chemotherapy, can help young patients with relapsed CD20 positive Non-Hodgkin Lymphoma feel better and improve their treatment results.
Related topics
Quick answers
How many Primary Mediastinal B Cell Lymphoma clinical trials are recruiting right now?
4, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.
Where are these trials running?
All of them have sites in United States. Each study page lists its sites and which ones are recruiting.
What phases are they in?
Phase 2: 2, Phase 1/2: 1. Trials with no phase listed are usually device, behavioural or observational studies.
How do I join one?
Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.
Find the studies that fit you
A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.